SEC Form SC 13G/A filed by Vickers Vantage Corp. I (Amendment)

$VCKA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $VCKA alert in real time by email
SC 13G/A 1 lf_sc13gz.htm SCHEDULE 13G/A Schedule 13G

 

OMB APPROVAL

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB Number:3235-0145 

Expires:Febuary 28, 2009 

Estimated average burden
hours per response ....10.4

 

 

SCHEDULE 13G

Under the Securities and Exchange Act of 1934

(Amendment No.        1        )*

 

Vickers Vantage Corp. I

(Name of Issuer)

 

Ordinary shares, par value $ 0.0001

(Title of Class of Securities)

 

G9440B107

(CUSIP Number)

 

 

November 9, 2022

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o  Rule 13d-1(b)

ý  Rule 13d-1(c)

o  Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


1


 

CUSIP No.    G9440B107

1.Names of Reporting Persons. 

I.R.S. Identification Nos. of above persons (entities only). 

Feis Equities LLC 

2.Check the Appropriate Box if a Member of a Group 

(a)o 

(b)o 

3.SEC Use Only 

4.Citizenship or Place of OrganizationState of Illinois 

Number of Shares Beneficially Owned by Each Reporting Person With

5.Sole Voting Power0 

6.Shared Voting Power0 

7.Sole Dispositive Power0 

8.Shared Dispositive Power0 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 

0 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

11.Percent of Class Represented by Amount in Row (9) 

0.00% 

12.Type of Reporting Person (See Instructions) 

OO-Limited Liability Company 


2


 

CUSIP No.    G9440B107

1.Names of Reporting Persons. 

I.R.S. Identification Nos. of above persons (entities only). 

Lawrence M. Feis 

2.Check the Appropriate Box if a Member of a Group 

(a)o 

(b)o 

3.SEC Use Only 

4.Citizenship or Place of OrganizationU.S.A. 

Number of Shares Beneficially Owned by Each Reporting Person With

5.Sole Voting Power0 

6.Shared Voting Power0 

7.Sole Dispositive Power0 

8.Shared Dispositive Power0 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 

0 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

11.Percent of Class Represented by Amount in Row (9)  

0.00% 

12.Type of Reporting Person (See Instructions) 

IN 


3


 

Item 1.

The name and address of the principal executive offices of the Issuer are:

Vickers Vantage Corp. I

1 Harbourfront Avenue, #16-06

Keppel Bay Tower

Singapore 098632

Item 2.

This statement on Schedule 13G is being filed by:

(a) Name of Person Filing 

 

(i)Feis Equities LLC 

(ii)Lawrence M. Feis 

 

 

 

 

 

(b)Address: 

The address of the business office of each of the Reporting Persons is:

 

20 North Wacker Drive

Suite 2115

Chicago, Illinois  60606

 

 

 

 

 

(c)Citizenship/Place: 

Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated hereto by reference for each Reporting Person.

 

(d)Title of Class of Securities: 

Ordinary shares, par value $ 0.0001 (the “Shares”)

 

(e)CUSIP Number: 

 

G9440B107

 

 

 


4


Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)oBroker or dealer registered under section 15 of the Act (15 U.S.C. 78o). 

(b)oBank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). 

(c)oInsurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). 

(d)oInvestment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). 

(e)oAn investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); 

(f)oAn employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); 

(g)oA parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

(h)oA savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 

(i)oA church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); 

(j)oGroup, in accordance with §240.13d-1(b)(1)(ii)(J). 

Item 4.  Ownership

 

The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for each Reporting Person and incorporated by reference herein.

 

The percentage set forth in row 11 of the cover page for each Reporting Person is based on 13,176,395 ordinary shares outstanding as of November 4,2022, as reported by the Issuer in its 10-Q filing for the period ending September 30, 2022, filed with the Securities and Exchange Commission on November 4, 2022.


5


 

Item 5.  Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ý

Item 6.  Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable.

Item 8.  Identification and Classification of Members of the Group

Not applicable.

Item 9.  Notice of Dissolution of Group

Not applicable.

Item 10.  Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


6


SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date:November 10, 2022 

 

 

 

 

Date:November 10, 2022 

 

FEIS EQUITIES LLC

By:/s/ Lawrence M. Feis 

            Managing Member LLC

 

 

LAWRENCE M. FEIS

By:/s/ Lawrence M. Feis 

 


7


 

 

EXHIBIT INDEX

 

Ex.

 

Page No.

 

 

 

A

Joint Filing Agreement

9


8


 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that the statement on Schedule 13G with respect to the ordinary shares of Vickers Vantage Corp. I dated as of November 10, 2022 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

 

FEIS EQUITIES LLC 

By:/s/ Lawrence M. Feis 

Managing Member LLC 

 

 

LAWRENCE M. FEIS 

By:/s/ Lawrence M. Feis 

 

Date:  November 10, 2022


9

Get the next $VCKA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VCKA

DatePrice TargetRatingAnalyst
More analyst ratings

$VCKA
Press Releases

Fastest customizable press release news feed in the world

See more

$VCKA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VCKA
SEC Filings

See more

$VCKA
Leadership Updates

Live Leadership Updates

See more
  • Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

    PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp

    $SRNE
    $VCKA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Scilex Holding Company a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO)

    SAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), who is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that Elizabeth Czerepak will join the company as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective May 18, 2022. Ms. Czerepak will be a member of the Scilex and Sorrento Executive Leadership Teams, reporting to Scilex's Chief Executive Officer and President, Jaisim Shah, and Sorr

    $SRNE
    $VCKA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill

    PALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors. Ms. Hamill brings to the Scilex board more than three decades of experience in the biopharma industry, serving most recently as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc. Prior to

    $SRNE
    $VCKA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$VCKA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more